治疗艾滋病新药--绥美凯

It is a new drug used to treat AIDS. It was approved for marketing by the US FDA in 2014 and approved for marketing in my country in 2018. It has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

Trimax is currently the only three-in-one compound drug containing dolutegravir (DTG). One tablet contains three antiviral drugs. Treatment drugs for different stages of viral infection are integrated in the same tablet. One tablet is a complete treatment plan. One tablet per day can achieve the effect of cocktail therapy without food restrictions.

AIDS is a chronic infectious disease. For patients, medication compliance is very important. Suimeikai is China's first complete single-piece three-in-one preparation with DTG as the core, filling the gap in single-piece compound preparations. Taking one pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance.

In addition, Suimeikai also has the characteristics of good tolerance, high resistance barrier, and low incidence of adverse reactions. Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%.

From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance.

In general, with the continuous advancement of medical technology, the launch of 1999 has brought a new choice to AIDS patients, which has played a good role in suppressing the virus and is very worthy of attention.